Ian R A Mackenzie

List of Publications by Year
in descending order

161	34,766	9264 74	6654 156
papers	citations	h-index	g-index

171	171	171	20580
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis. Science, 2006, 314, 130-133.	12.6	5,422
2	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
3	Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature, 2006, 442, 916-919.	27.8	1,816
4	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2012, 71, 362-381.	1.7	1,599
5	Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration. Acta Neuropathologica, 2007, 114, 5-22.	7.7	978
6	Nomenclature and nosology for neuropathologic subtypes of frontotemporal lobar degeneration: an update. Acta Neuropathologica, 2010, 119, 1-4.	7.7	854
7	Pathological TDPâ€43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Annals of Neurology, 2007, 61, 427-434.	5.3	840
8	A harmonized classification system for FTLD-TDP pathology. Acta Neuropathologica, 2011, 122, 111-113.	7.7	817
9	ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import. EMBO Journal, 2010, 29, 2841-2857.	7.8	717
10	A new subtype of frontotemporal lobar degeneration with FUS pathology. Brain, 2009, 132, 2922-2931.	7.6	628
11	Progranulin Deficiency Promotes Circuit-Specific Synaptic Pruning by Microglia via Complement Activation. Cell, 2016, 165, 921-935.	28.9	558
12	Mutations in progranulin are a major cause of ubiquitin-positive frontotemporal lobar degeneration. Human Molecular Genetics, 2006, 15, 2988-3001.	2.9	529
13	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	8.1	493
14	Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nature Genetics, 2010, 42, 234-239.	21.4	479
15	Sortilin-Mediated Endocytosis Determines Levels of the Frontotemporal Dementia Protein, Progranulin. Neuron, 2010, 68, 654-667.	8.1	465
16	TDP-43 in Familial and Sporadic Frontotemporal Lobar Degeneration with Ubiquitin Inclusions. American Journal of Pathology, 2007, 171, 227-240.	3.8	446
17	Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis. PLoS Genetics, 2008, 4, e1000193.	3.5	393
18	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	7.7	380

#	Article	IF	Citations
19	Nomenclature for neuropathologic subtypes of frontotemporal lobar degeneration: consensus recommendations. Acta Neuropathologica, 2009, 117, 15-18.	7.7	377
20	Neuropathological background of phenotypical variability in frontotemporal dementia. Acta Neuropathologica, 2011, 122, 137-153.	7.7	375
21	Advances in understanding the molecular basis of frontotemporal dementia. Nature Reviews Neurology, 2012, 8, 423-434.	10.1	353
22	hnRNP A3 binds to GGGGCC repeats and is a constituent of p62-positive/TDP43-negative inclusions in the hippocampus of patients with C9orf72 mutations. Acta Neuropathologica, 2013, 125, 413-423.	7.7	302
23	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	10.2	302
24	Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathologica, 2006, 112, 539-549.	7.7	298
25	Dipeptide repeat protein pathology in C9ORF72 mutation cases: clinico-pathological correlations. Acta Neuropathologica, 2013, 126, 859-879.	7.7	298
26	TDP-43 in the Ubiquitin Pathology of Frontotemporal Dementia With VCP Gene Mutations. Journal of Neuropathology and Experimental Neurology, 2007, 66, 152-157.	1.7	295
27	Phosphorylated TDP-43 in Alzheimerâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica, 2009, 117, 125-136.	7.7	294
28	The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain, 2006, 129, 3081-3090.	7.6	291
29	Ubiquitinated pathological lesions in frontotemporal lobar degeneration contain the TAR DNA-binding protein, TDP-43. Acta Neuropathologica, 2007, 113, 521-533.	7.7	274
30	Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Human Molecular Genetics, 2008, 17, 3631-3642.	2.9	271
31	Arginine methylation next to the PY-NLS modulates Transportin binding and nuclear import of FUS. EMBO Journal, 2012, 31, 4258-4275.	7.8	266
32	Molecular neuropathology of frontotemporal dementia: insights into disease mechanisms from postmortem studies. Journal of Neurochemistry, 2016, 138, 54-70.	3.9	252
33	FET proteins TAF15 and EWS are selective markers that distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS mutations. Brain, 2011, 134, 2595-2609.	7.6	247
34	Abundant FUS-immunoreactive pathology in neuronal intermediate filament inclusion disease. Acta Neuropathologica, 2009, 118, 605-616.	7.7	237
35	FUS pathology in basophilic inclusion body disease. Acta Neuropathologica, 2009, 118, 617-627.	7.7	222
36	FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration. Acta Neuropathologica, 2010, 120, 33-41.	7.7	222

#	Article	IF	Citations
37	Novel Ubiquitin Neuropathology in Frontotemporal Dementia WithValosin-Containing ProteinGene Mutations. Journal of Neuropathology and Experimental Neurology, 2006, 65, 571-581.	1.7	206
38	Quantitative analysis and clinico-pathological correlations of different dipeptide repeat protein pathologies in C9ORF72 mutation carriers. Acta Neuropathologica, 2015, 130, 845-861.	7.7	204
39	Clinical and pathological features of familial frontotemporal dementia caused by C9ORF72 mutation on chromosome 9p. Brain, 2012, 135, 709-722.	7.6	201
40	Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477Câ†'T (Arg493X) mutation: an international initiative. Lancet Neurology, The, 2007, 6, 857-868.	10.2	199
41	Progranulin in frontotemporal lobar degeneration and neuroinflammation. Journal of Neuroinflammation, 2007, 4, 7.	7.2	194
42	Phenotypic Variability of Gerstmann-Straussler-Scheinker Disease is Associated with Prion Protein Heterogeneity. Journal of Neuropathology and Experimental Neurology, 1998, 57, 979-988.	1.7	182
43	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
44	Clinical, neuroimaging and neuropathological features of a new chromosome 9p-linked FTD-ALS family. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 196-203.	1.9	170
45	The neuropathology associated with repeat expansions in the C9ORF72 gene. Acta Neuropathologica, 2014, 127, 347-357.	7.7	164
46	Pathological heterogeneity in amyotrophic lateral sclerosis with FUS mutations: two distinct patterns correlating with disease severity and mutation. Acta Neuropathologica, 2011, 122, 87-98.	7.7	153
47	The role of transactive response DNA-binding protein-43 in amyotrophic lateral sclerosis and frontotemporal dementia. Current Opinion in Neurology, 2008, 21, 693-700.	3.6	150
48	Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis. Science Translational Medicine, 2017, 9, .	12.4	147
49	Synaptic dysfunction in progranulin-deficient mice. Neurobiology of Disease, 2012, 45, 711-722.	4.4	144
50	Ubiquitin Immunohistochemistry Suggests Classic Motor Neuron Disease, Motor Neuron Disease With Dementia, and Frontotemporal Dementia of the Motor Neuron Disease Type Represent a Clinicopathologic Spectrum. Journal of Neuropathology and Experimental Neurology, 2005, 64, 730-739.	1.7	143
51	Distinct pathological subtypes of FTLD-FUS. Acta Neuropathologica, 2011, 121, 207-218.	7.7	139
52	Clinical and pathological features of amyotrophic lateral sclerosis caused by mutation in the C9ORF72 gene on chromosome 9p. Acta Neuropathologica, 2012, 123, 409-417.	7.7	137
53	TMEM106B protects C9ORF72 expansion carriers against frontotemporal dementia. Acta Neuropathologica, 2014, 127, 397-406.	7.7	133
54	Prevalence of amyloidâ€Î²2 pathology in distinct variants of primary progressive aphasia. Annals of Neurology, 2018, 84, 729-740.	5.3	132

#	Article	IF	Citations
55	Atypical frontotemporal lobar degeneration with ubiquitin-positive, TDP-43-negative neuronal inclusions. Brain, 2008, 131, 1282-1293.	7.6	131
56	Genome-wide Screen Identifies rs646776 near Sortilin as a Regulator of Progranulin Levels in Human Plasma. American Journal of Human Genetics, 2010, 87, 890-897.	6.2	130
57	Central neurocytoma. , 1999, 85, 1606-1610.		122
58	The neuropathology and clinical phenotype of FTD with progranulin mutations. Acta Neuropathologica, 2007, 114, 49-54.	7.7	119
59	A Reassessment of the Neuropathology of Frontotemporal Dementia Linked to Chromosome 3. Journal of Neuropathology and Experimental Neurology, 2007, 66, 884-891.	1.7	118
60	Î±-Internexin Is Present in the Pathological Inclusions of Neuronal Intermediate Filament Inclusion Disease. American Journal of Pathology, 2004, 164, 2153-2161.	3.8	116
61	Progranulin: normal function and role in neurodegeneration. Journal of Neurochemistry, 2008, 104, 287-297.	3.9	114
62	Genetic and Clinical Features of Progranulin-Associated Frontotemporal Lobar Degeneration. Archives of Neurology, 2011, 68, 488.	4.5	108
63	A family with tau-negative frontotemporal dementia and neuronal intranuclear inclusions linked to chromosome 17. Brain, 2006, 129, 853-867.	7.6	102
64	Fus gene mutations in familial and sporadic amyotrophic lateral sclerosis. Muscle and Nerve, 2010, 42, 170-176.	2.2	101
65	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
66	CNS-derived extracellular vesicles from superoxide dismutase 1 (SOD1)G93A ALS mice originate from astrocytes and neurons and carry misfolded SOD1. Journal of Biological Chemistry, 2019, 294, 3744-3759.	3.4	97
67	Targeted manipulation of the sortilinâ€“progranulin axis rescues progranulin haploinsufficiency. Human Molecular Genetics, 2014, 23, 1467-1478.	2.9	96
68	Frontotemporal lobar degeneration: current perspectives. Neuropsychiatric Disease and Treatment, 2014, 10, 297.	2.2	95
69	Mutations in progranulin explain atypical phenotypes with variants in MAPT. Brain, 2006, 129, 3124-3126.	7.6	91
70	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
71	Mechanisms of disease in frontotemporal lobar degeneration: gain of function versus loss of function effects. Acta Neuropathologica, 2012, 124, 373-382.	7.7	89
72	<scp>TMEM</scp>106B p.T185S regulates <scp>TMEM</scp>106B protein levels: implications for frontotemporal dementia. Journal of Neurochemistry, 2013, 126, 781-791.	3.9	87

#	Article	IF	Citations
73	Novel antibodies reveal presynaptic localization of C9orf72 protein and reduced protein levels in C9orf72 mutation carriers. Acta Neuropathologica Communications, 2018, 6, 72.	5.2	87
74	FUSâ€Immunoreactive Intranuclear Inclusions in Neurodegenerative Disease. Brain Pathology, 2010, 20, 589-597.	4.1	84
75	C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology, 2013, 81, 1332-1341.	1.1	84
76	Length of normal alleles of C9ORF72 GGGGCC repeat do not influence disease phenotype. Neurobiology of Aging, 2012, 33, 2950.e5-2950.e7.	3.1	83
77	Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathologica, 2017, 134, 79-96.	7.7	83
78	Dementia lacking distinctive histology (DLDH) revisited. Acta Neuropathologica, 2006, 112, 551-559.	7.7	80
79	TDP-43-negative FTLD-U is a significant new clinico-pathological subtype of FTLD. Acta Neuropathologica, 2008, 116, 147-157.	7.7	77
80	rs5848 polymorphism and serum progranulin level. Journal of the Neurological Sciences, 2011, 300, 28-32.	0.6	77
81	The molecular genetics and neuropathology of frontotemporal lobar degeneration: recent developments. Neurogenetics, 2007, 8, 237-248.	1.4	76
82	Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS. Acta Neuropathologica, 2016, 131, 587-604.	7.7	76
83	Transportin 1 accumulates specifically with FET proteins but no other transportin cargos in FTLD-FUS and is absent in FUS inclusions in ALS with FUS mutations. Acta Neuropathologica, 2012, 124, 705-716.	7.7	74
84	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	3.1	74
85	FET proteins in frontotemporal dementia and amyotrophic lateral sclerosis. Brain Research, 2012, 1462, 40-43.	2.2	71
86	Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseases. Cell, 2022, 185, 1346-1355.e15.	28.9	70
87	The molecular basis of frontotemporal dementia. Expert Reviews in Molecular Medicine, 2009, 11, e23.	3.9	69
88	Early dipeptide repeat pathology in a frontotemporal dementia kindred with C9ORF72 mutation and intellectual disability. Acta Neuropathologica, 2014, 127, 451-458.	7.7	67
89	Genetic modifiers in carriers of repeat expansions in the C9ORF72 gene. Molecular Neurodegeneration, 2014, 9, 38.	10.8	63
90	Senile plaques do not progressively accumulate with normal aging. Acta Neuropathologica, 1994, 87, 520-525.	7.7	61

#	Article	IF	Citations
91	Anterior brain glucose hypometabolism predates dementia in progranulin mutation carriers. Neurology, 2013, 81, 1322-1331.	1.1	60
92	Frontotemporal degeneration, the next therapeutic frontier: Molecules and animal models for frontotemporal degeneration drug development. Alzheimer's and Dementia, 2013, 9, 176-188.	0.8	58
93	Absence of FUS-immunoreactive pathology in frontotemporal dementia linked to chromosome 3 (FTD-3) caused by mutation in the CHMP2B gene. Acta Neuropathologica, 2009, 118, 719-720.	7.7	56
94	The Comprehensive Assessment of Neurodegeneration and Dementia: Canadian Cohort Study. Canadian Journal of Neurological Sciences, 2019, 46, 499-511.	0.5	56
95	The Neuropathology of FTD Associated With ALS. Alzheimer Disease and Associated Disorders, 2007, 21, S44-S49.	1.3	55
96	Interactions between ALS-linked FUS and nucleoporins are associated with defects in the nucleocytoplasmic transport pathway. Nature Neuroscience, 2021, 24, 1077-1088.	14.8	54
97	?-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathologica, 2004, 108, 213-23.	7.7	50
98	Jump from Pre-mutation to Pathologic Expansion in C9orf72. American Journal of Human Genetics, 2015, 96, 962-970.	6.2	50
99	Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. Journal of Neural Transmission, 2010, 117, 227-239.	2.8	48
100	The advantages of frontotemporal degeneration drug development (partÂ2Âof frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	0.8	48
101	eEF2K inhibition blocks AÎ²42 neurotoxicity by promoting an NRF2 antioxidant response. Acta Neuropathologica, 2017, 133, 101-119.	7.7	48
102	Activity of translation regulator eukaryotic elongation factor-2 kinase is increased in Parkinson disease brain and its inhibition reduces alpha synuclein toxicity. Acta Neuropathologica Communications, 2018, 6, 54.	5.2	48
103	The relationship between extramotor ubiquitin-immunoreactive neuronal inclusions and dementia in motor neuron disease. Acta Neuropathologica, 2003, 105, 98-102.	7.7	47
104	Sex differences in the prevalence of genetic mutations in FTD and ALS. Neurology, 2017, 89, 1633-1642.	1.1	47
105	LATE to the PART-y. Brain, 2019, 142, e47-e47.	7.6	44
106	Two cases of rheumatoid meningitis. Neuropathology, 2016, 36, 93-102.	1.2	43
107	Amyloid Beta Immunoreactivity in the Retinal Ganglion Cell Layer of the Alzheimerâ€™s Eye. Frontiers in Neuroscience, 2020, 14, 758.	2.8	42
108	Reduced hn <scp>RNPA</scp> 3 increases C9orf72 repeat <scp>RNA</scp> levels and dipeptideâ€repeat protein deposition. EMBO Reports, 2016, 17, 1314-1325.	4.5	39

#	Article	IF	Citations
109	Clinical and neuropathological features of ALS/FTD with TIA1 mutations. Acta Neuropathologica Communications, 2017, 5, 96.	5.2	38
110	Individualized atrophy scores predict dementia onset in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 37-48.	0.8	38
111	Neuronal intranuclear inclusions distinguish familial FTD-MND type from sporadic cases. Acta Neuropathologica, 2003, 105, 543-548.	7.7	37
112	Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathologica, 2020, 139, 83-98.	7.7	37
113	Development and validation of a novel dementia of Alzheimer's type (DAT) score based on metabolism FDG-PET imaging. NeuroImage: Clinical, 2018, 18, 802-813.	2.7	35
114	Novel Types of Frontotemporal Lobar Degeneration: Beyond Tau and TDP-43. Journal of Molecular Neuroscience, 2011, 45, 402-408.	2.3	33
115	Microglial lysosome dysfunction contributes to white matter pathology and TDP-43 proteinopathy in GRN-associated FTD. Cell Reports, 2021, 36, 109581.	6.4	33
116	Assessment of executive function declines in presymptomatic and mildly symptomatic familial frontotemporal dementia: NIHâ€EXAMINER as a potential clinical trial endpoint. Alzheimer's and Dementia, 2020, 16, 11-21.	0.8	32
117	Spinal cord homogenates from SOD1 familial amyotrophic lateral sclerosis induce SOD1 aggregation in living cells. PLoS ONE, 2017, 12, e0184384.	2.5	32
118	Proposed research criteria for prodromal behavioural variant frontotemporal dementia. Brain, 2022, 145, 1079-1097.	7.6	30
119	Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimer's and Dementia, 2020, 16, 49-59.	0.8	27
120	Gray matter changes in asymptomatic C9orf72 and GRN mutation carriers. NeuroImage: Clinical, 2018, 18, 591-598.	2.7	26
121	Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance. Advances in Experimental Medicine and Biology, 2021, 1281, 201-217.	1.6	26
122	Fused in Sarcoma Neuropathology in Neurodegenerative Disease. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a024299.	6.2	25
123	Clinicopathologic correlations in a family with aTBK1mutation presenting as primary progressive aphasia and primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 568-575.	1.7	24
124	Drusen in the Peripheral Retina of the Alzheimerâ€™s Eye. Current Alzheimer Research, 2018, 15, 743-750.	1.4	24
125	Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative study. Acta Neuropathologica, 2004, 107, 336-340.	7.7	23
126	The spectrum and severity of FUS-immunoreactive inclusions in the frontal and temporal lobes of ten cases of neuronal intermediate filament inclusion disease. Acta Neuropathologica, 2011, 121, 219-228.	7.7	23

#	Article	IF	Citations
127	Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLDâ€“TDP subtypes. Acta Neuropathologica, 2020, 140, 645-658.	7.7	23
128	Neuronal Intranuclear Inclusions Distinguish Familial FTD-MND Type from Sporadic Cases. Dementia and Geriatric Cognitive Disorders, 2004, 17, 333-336.	1.5	22
129	Early Neuropsychological Characteristics of Progranulin Mutation Carriers. Journal of the International Neuropsychological Society, 2014, 20, 694-703.	1.8	21
130	Multiple brain pathologies in dementia are common. European Geriatric Medicine, 2010, 1, 259-265.	2.8	20
131	TDP-43 pathology in primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 52-58.	1.7	20
132	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	5.9	19
133	Premature termination codon readthrough upregulates progranulin expression and improves lysosomal function in preclinical models of GRN deficiency. Molecular Neurodegeneration, 2020, 15, 21.	10.8	19
134	Progressive Anomia Revisited: Focal Degeneration Associated with Progranulin Gene Mutation. Neurocase, 2008, 13, 366-377.	0.6	17
135	Î±-Synuclein pathology in Parkinson disease activates homeostatic NRF2 anti-oxidant response. Acta Neuropathologica Communications, 2021, 9, 105.	5.2	17
136	FDG-PET in presymptomatic C9orf72 mutation carriers. NeuroImage: Clinical, 2021, 31, 102687.	2.7	16
137	Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiology of Aging, 2019, 83, 54-62.	3.1	14
138	Mutations in protein N-arginine methyltransferases are not the cause of FTLD-FUS. Neurobiology of Aging, 2013, 34, 2235.e11-2235.e13.	3.1	13
139	Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex, 2021, 139, 99-115.	2.4	12
140	Developmental Delay, Treatment-Resistant Psychosis, and Early-Onset Dementia in a Man With 22q11 Deletion Syndrome and Huntingtonâ€™s Disease. American Journal of Psychiatry, 2018, 175, 400-407.	7.2	9
141	The contribution of behavioral features to caregiver burden in FTLD spectrum disorders. Alzheimer's and Dementia, 2022, 18, 1635-1649.	0.8	9
142	Neuropathology of primary lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 47-51.	1.7	8
143	The spectrum of disease and tau pathology of nodding syndrome in Uganda. Brain, 2023, 146, 954-967.	7.6	8
144	Spatial patterns of FUS-immunoreactive neuronal cytoplasmic inclusions (NCI) in neuronal intermediate filament inclusion disease (NIFID). Journal of Neural Transmission, 2011, 118, 1651-1657.	2.8	7

#	Article	IF	Citations
145	Detection and characterization of TDP-43 in human cells and tissues by multiple reaction monitoring mass spectrometry. Clinical Mass Spectrometry, 2019, 14, 66-73.	1.9	7
146	Prodromal neuroinvasion of pathological Î±-synuclein in brainstem reticular nuclei and white matter lesions in a model of Î±-synucleinopathy. Brain Communications, 2021, 3, fcab104.	3.3	7
147	Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease. BMC Neurology, 2006, 6, 32.	1.8	6
148	Decreased Prefrontal Activation during Matrix Reasoning in Predementia Progranulin Mutation Carriers. Journal of Alzheimer's Disease, 2018, 62, 583-589.	2.6	5
149	Expanding the Phenotype of Frontotemporal Lobar Degeneration With FUS-Positive Pathology (FTLD-FUS). Journal of Neuropathology and Experimental Neurology, 2020, 79, 809-812.	1.7	5
150	Aptamer-based enrichment of TDP-43 from human cells and tissues with quantification by HPLC-MS/MS. Journal of Neuroscience Methods, 2021, 363, 109344.	2.5	5
151	Longâ€standing multiple system atrophyâ€Parkinsonism with limbic and FTLDâ€type Î±â€synuclein pathology. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	4
152	An Unusual Case of Rabies Encephalitis. Canadian Journal of Neurological Sciences, 2016, 43, 852-855.	0.5	3
153	Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis. Journal of Psychiatry and Brain Science, 2019, 4, .	0.5	3
154	Applying the Alzheimer Disease ATN Diagnostic Framework in Atypical Dementia. Alzheimer Disease and Associated Disorders, 2020, 34, 357-359.	1.3	3
155	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.5	2
156	A mitochondrial DNA D loop insertion detected almost exclusively in non-replicating tissues with maternal inheritance across three generations. Mitochondrion, 2019, 46, 298-301.	3.4	1
157	A lady with weakness, fasciculations, and failing memory. , 0, , 90-97.		0
158	Young man with progressive speech impairment and weakness. , 0, , 105-114.		0
159	Amyloid Deposits in the Retina of the Human Eye are Biomarkers of Two Different Diseases. , 2020, , .		0
160	Left-Handed Man with Memory Complaints. , 2021, , 49-53.		0
161	TDPâ€43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. FASEB Journal, 2007, 21, A25.	0.5	0